BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 23719407)

  • 1. ProExC is a novel marker for distinguishing between primary endometrial and endocervical adenocarcinomas.
    Esheba GE
    J Egypt Natl Canc Inst; 2013 Jun; 25(2):87-93. PubMed ID: 23719407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas.
    Kong CS; Beck AH; Longacre TA
    Am J Surg Pathol; 2010 Jul; 34(7):915-26. PubMed ID: 20534993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study.
    Liao CL; Lee MY; Tyan YS; Kok LF; Wu TS; Koo CL; Wang PH; Chao KC; Han CP
    J Transl Med; 2009 May; 7():37. PubMed ID: 19476621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding the p16(INK4a) marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
    Han CP; Lee MY; Kok LF; Ruan A; Wu TS; Cheng YW; Tyan YS; Lin CY
    Int J Gynecol Pathol; 2009 Sep; 28(5):489-96. PubMed ID: 19696622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of high-risk human papillomavirus DNA and immunohistochemical expressions of p16, vimentin, ER, and PR in primary endocervical and endometrial adenocarcinomas.
    Xiong Y; Xiong YY; Xu ZG
    Eur J Gynaecol Oncol; 2016 Aug; 37(4):517-521. PubMed ID: 29894077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ancillary p16(INK4a) adds no meaningful value to the performance of ER/PR/Vim/CEA panel in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
    Yao CC; Kok LF; Lee MY; Wang PH; Wu TS; Tyan YS; Cheng YW; Kung MF; Han CP
    Arch Gynecol Obstet; 2009 Sep; 280(3):405-13. PubMed ID: 19153755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p16 INK4 and CEA can be mutually exchanged with confidence between both relevant three-marker panels (ER/Vim/CEA and ER/Vim/p16 INK4) in distinguishing primary endometrial adenocarcinomas from endocervical adenocarcinomas in a tissue microarray study.
    Han CP; Lee MY; Tyan YS; Kok LF; Yao CC; Wang PH; Hsu JD; Tseng SW
    Virchows Arch; 2009 Oct; 455(4):353-61. PubMed ID: 19763614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A reappraisal of three-marker (ER/Vim/CEA), four-marker (ER/Vim/CEA/PR), and five-marker (ER/Vim/CEA/PR/p16INK4a) panels in the diagnostic distinction between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
    Han CP; Lee MY; Kok LF; Wu TS; Cheng YW; Wang PH; Yue CH; Tyan YS
    Arch Gynecol Obstet; 2010 May; 281(5):845-50. PubMed ID: 19847454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Diagnosis between Primary Endocervical and Endometrial Adenocarcinoma using Immunohistochemical Staining of Estrogen Receptor, Vimentin, Carcinoembryonic Antigen and p16.
    Yanaranop M; Ayuwat S; Nakrangsee S
    J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S106-15. PubMed ID: 27266224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinguishing between primary endocervical and endometrial adenocarcinomas: is a 2-marker (Vim/CEA) panel enough?
    Liao CL; Hsu JD; Lee MY; Kok LF; Li YJ; Wang PH; Yao CC; Han CP
    Virchows Arch; 2010 Apr; 456(4):377-86. PubMed ID: 20221633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inclusion of MUC1 (Ma695) in a panel of immunohistochemical markers is useful for distinguishing between endocervical and endometrial mucinous adenocarcinoma.
    Khoury T; Tan D; Wang J; Intengan M; Yang J; Alrawi S; Yan P; Byrd JC
    BMC Clin Pathol; 2006 Jan; 6():1. PubMed ID: 16409624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of ER, VIM, CEA and p16 detection in the diagnosis and differential diagnosis of primary endocervical and endometrial adenocarcinomas].
    Hu WW; Tao JH; Li GM; Xu X; Yang XM
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):526-8, 531. PubMed ID: 20335127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas.
    McCluggage WG; Sumathi VP; McBride HA; Patterson A
    Int J Gynecol Pathol; 2002 Jan; 21(1):11-5. PubMed ID: 11781517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma: a comparative tissue microarray study of 76 tumors.
    Jones MW; Onisko A; Dabbs DJ; Elishaev E; Chiosea S; Bhargava R
    Int J Gynecol Cancer; 2013 Feb; 23(2):380-4. PubMed ID: 23318908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
    Yemelyanova A; Vang R; Seidman JD; Gravitt PE; Ronnett BM
    Am J Surg Pathol; 2009 Jun; 33(6):914-24. PubMed ID: 19295407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin.
    Saad RS; Mashhour M; Noftech-Mozes S; Ismiil N; Dubé V; Ghorab Z; Faragalla H; Khalifa MA
    Int J Gynecol Pathol; 2012 Jan; 31(1):57-65. PubMed ID: 22123724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study.
    Castrillon DH; Lee KR; Nucci MR
    Int J Gynecol Pathol; 2002 Jan; 21(1):4-10. PubMed ID: 11781516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma.
    McCluggage WG; Jenkins D
    Int J Gynecol Pathol; 2003 Jul; 22(3):231-5. PubMed ID: 12819388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection.
    Ansari-Lari MA; Staebler A; Zaino RJ; Shah KV; Ronnett BM
    Am J Surg Pathol; 2004 Feb; 28(2):160-7. PubMed ID: 15043304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five commonly used markers (p53, TTF1, CK7, CK20, and CK34betaE12) are of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study.
    Han CP; Kok LF; Lee MY; Wu TS; Ruan A; Cheng YW; Wang PH; Koo CL; Tyan YS
    Arch Gynecol Obstet; 2010 Feb; 281(2):317-23. PubMed ID: 19444461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.